

Appendix 1

(((((((((Fibromatosis, Aggressive[MeSH Terms]) OR (Aggressive Fibromatoses[Title/Abstract])) OR (Aggressive Fibromatosis[Title/Abstract])) OR (Fibromatoses, Aggressive[Title/Abstract])) OR (Desmoid[Title/Abstract])) OR (Desmoids[Title/Abstract])) OR (Desmoid-type fibromatosis[Title/Abstract])) OR (Desmoid Tumors[Title/Abstract])) AND ((((((((((Radiofrequency Ablation[MeSH Terms]) OR (Ablation, Radiofrequency[Title/Abstract])) OR (Radio Frequency Ablation[Title/Abstract])) OR (Ablation, Radio Frequency[Title/Abstract])) OR (Radio-Frequency Ablation[Title/Abstract])) OR (Ablation, Radio-Frequency[Title/Abstract])) OR (RFA[Title/Abstract])) OR ((microwave ablation[Title/Abstract]) OR (MWA[Title/Abstract]))) OR (((High-Intensity Focused Ultrasound Ablation[MeSH Terms]) OR (High Intensity Focused Ultrasound Ablation[Title/Abstract])) OR (HIFU[Title/Abstract]))) OR (((Cryosurgery[MeSH Terms]) OR (Cryosurgeries[Title/Abstract])) OR (Cryoablation[Title/Abstract])) OR (Cryoablations[Title/Abstract])) OR (((((Laser Therapy[MeSH Terms]) OR (Ablation, Laser[Title/Abstract])) OR (Laser Ablation[Title/Abstract])) OR (Laser Tissue Ablation[Title/Abstract])) OR (Tissue Ablation, Laser[Title/Abstract])) OR (Ablation, Laser Tissue[Title/Abstract]))))

Table S1 Risk of bias in the included cohort studies (according to the MINORS quality assessment tool)

Author	A clearly stated aim	Inclusion of consecutive patients	Prospective collection of data	Endpoints appropriate to the aim of the study	Unbiased assessment of the study endpoint	Follow-up period appropriate to the aim of the study	Loss to follow-up less than 5%	Prospective calculation of the study size	Total quality score
Kujak <i>et al.</i> (18)	2	2	1	2	1	2	2	0	12
Wang <i>et al.</i> (19)	2	2	2	2	1	2	2	0	13
Havez <i>et al.</i> (20)	2	2	1	2	2	1	2	0	12
Schmitz <i>et al.</i> (23)	2	1	1	2	1	1	2	0	10
Avedian <i>et al.</i> (22)	2	2	2	1	2	1	1	0	11
Zhao <i>et al.</i> (21)	2	1	1	2	1	1	2	0	10
Ghanouni <i>et al.</i> (24)	2	2	2	2	2	1	2	0	13
Najafi <i>et al.</i> (25)	2	1	1	2	1	2	2	0	11
Redifer <i>et al.</i> (26)	2	1	1	1	1	1	2	0	9
Bouhamama <i>et al.</i> (28)	2	1	1	2	1	1	2	0	10
Saltiel <i>et al.</i> (27)	2	1	1	2	1	2	2	0	11
Mandel <i>et al.</i> (32)	2	2	2	2	1	2	2	0	13
Kurtz <i>et al.</i> (30)	2	2	2	2	2	2	2	1	15
Auloge <i>et al.</i> (13)	2	2	2	2	1	1	2	0	12
Zhang <i>et al.</i> (12)	2	2	2	2	2	1	2	0	13
Efrima <i>et al.</i> (31)	2	1	1	2	1	1	2	0	10
Yan <i>et al.</i> (29)	2	1	1	2	1	1	1	0	9
Martínez-Martínez <i>et al.</i> (14)	2	2	1	2	2	1	2	0	12
Zhong <i>et al.</i> (33)	2	1	1	2	1	2	2	0	11
Johnston <i>et al.</i> (36)	2	2	2	2	1	1	2	0	12
Colak <i>et al.</i> (35)	2	1	1	2	1	1	2	0	10
Mo <i>et al.</i> (34)	2	2	1	2	1	0	2	0	10
Yang <i>et al.</i> (37)	2	2	2	2	1	1	2	0	12

MINORS, methodological index for nonrandomized studies.